#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4442	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2451	528.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1609	1609	C	632	C	576	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6808	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4086	498.9	0	.	n	.	0	T695C	SNP	695	695	T	1319	1319	C	481	C,A	434,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6808	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4086	498.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1961	1961	A	597	A,G	544,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6808	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4086	498.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2595	2595	C	598	C,A	546,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6808	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4086	498.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2669	2669	A	631	A,C	573,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6808	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4086	498.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3221	3221	C	644	C,T	557,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6808	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4086	498.9	0	HET	.	.	.	A848G	.	848	848	A	1472	1472	A	502	A,G	330,124	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	640	folP	852	852	100.0	folP.l15.c4.ctg.1	2026	94.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1222	1224	AGC	127;128;127	A;G;C	118;120;115	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1362	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3921	104.0	1	SNP	p	S91F	0	.	.	271	273	TCC	845	847	TCC	112;113;113	T;C;C	103;102;99	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1362	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3921	104.0	1	SNP	p	D95G	0	.	.	283	285	GAC	857	859	GAC	110;111;112	G;A;C	101;102;104	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1362	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3921	104.0	1	SNP	p	D95N	0	.	.	283	285	GAC	857	859	GAC	110;111;112	G;A;C	101;102;104	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	1	1	539	658	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1941	101.8	0	.	p	.	0	A40P	NONSYN	118	120	GCC	780	782	CCC	158;158;157	C,A;C;C	143,1;140;144	.	.
mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	1	1	539	658	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1941	101.8	1	SNP	p	G45D	0	.	.	133	135	GGC	795	797	GGC	163;163;163	G;G,C;C	146;148,1;148	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1442	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3537	122.2	1	SNP	p	D86N	0	.	.	256	258	GAC	856	858	GAC	148;148;148	G;A;C	135;126;134	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1442	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3537	122.2	1	SNP	p	S87W	0	.	.	259	261	AGT	859	861	AGT	148;150;149	A;G;T,G	129;136;130,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1442	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3537	122.2	1	SNP	p	S87R	0	.	.	259	261	AGT	859	861	AGT	148;150;149	A;G;T,G	129;136;130,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1442	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3537	122.2	1	SNP	p	S87I	0	.	.	259	261	AGT	859	861	AGT	148;150;149	A;G;T,G	129;136;130,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1442	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3537	122.2	1	SNP	p	S88P	0	.	.	262	264	TCC	862	864	TCC	149;150;150	T,G;C;C	134,1;134;137	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1184	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3303	107.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1849	1851	GGC	140;139;139	G;G,T,C;C	125;121,1,1;121	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2962	106.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1585	1587	GCA	145;144;144	G;C;A,G	129;130;127,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2962	106.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1588	1590	ATC	145;145;146	A;T;C	130;128;131	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2962	106.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1600	1602	GTG	142;140;141	G,T;T,C;G,T	128,1;128,1;128,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2962	106.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1600	1602	GTG	142;140;141	G,T;T,C;G,T	128,1;128,1;128,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2962	106.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2104	2106	ACC	104;106;105	A,C;C;C	89,1;100;101	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2962	106.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2158	2160	GCG	117;119;120	G,A;C,G,A;G,C	100,1;83,1,1;91,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2962	106.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2158	2160	GCG	117;119;120	G,A;C,G,A;G,C	100,1;83,1,1;91,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2962	106.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2281	2283	GGC	127;127;127	G,C;G,C;C,A	114,1;116,1;116,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2962	106.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2290	2292	GGC	128;128;126	G;G;C	111;118;115	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2962	106.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2308	2310	CCG	126;127;128	C;C;G	110;113;109	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1512	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3641	124.5	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1871	1873	CTG	155;155;156	C;T,C;G	129;132,2;131	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	800	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2450	97.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	814	814	C	134	C	119	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	808	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1834	129.8	0	.	p	.	0	F135L	NONSYN	403	405	TTT	852	854	CTT	159;158;158	C,A;T,G;T	143,1;143,1;137	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	808	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1834	129.8	0	.	p	.	0	R143G	NONSYN	427	429	AGA	876	878	GGA	156;157;157	G;G;A	140;139;141	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	808	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1834	129.8	0	.	p	.	0	D171G	NONSYN	511	513	GAT	960	962	GGT	159;160;160	G;G;T	146;143;146	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	808	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1834	129.8	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1014	1016	AGC	157;155;155	A;G;C	139;137;136	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	808	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1834	129.8	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1080	1080	T	150	T	140	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	808	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1834	129.8	1	SNP	p	G120K	0	.	.	358	360	GGT	807	809	GGT	170;170;170	G;G;T,G	159;155;149,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	808	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1834	129.8	1	SNP	p	A121D	0	.	.	361	363	GCC	810	812	GCC	170;169;169	G;C;C	155;158;157	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	808	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1834	129.8	1	SNP	p	A121N	0	.	.	361	363	GCC	810	812	GCC	170;169;169	G;C;C	155;158;157	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2692	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5373	150.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2259	2261	AAT	166;166;167	A;A,G;T	153;152,1;155	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	426	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1422	88.5	1	SNP	p	V57M	1	.	.	169	171	ATG	702	704	ATG	150;150;150	A;T;G	136;137;137	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
